Bevacizumab is a recombinant human monoclonal antibody targeting vascular endothelial growth factor (VEGF) receptors on the surface of endothelial cells, which could restore vascular permeability and reduce brain edema (14). The gene discussed is VEGFA; the disease is brain edema.